Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.52 --0%
EPS Growth %: -50.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
OMID, BCBP, BCML, More
EPS Growth %: -50.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
OMID, BCBP, BCML, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Williams Trading Downgrades Birkenstock Holding plc (BIRK) to Sell, 'Stock Less Comfortable than the Shoes'
- Punjab National Bank (PNB:IN) PT Raised to INR134 at JPMorgan
- JPMorgan Upgrades Intel (INTC) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
